Axsome Therapeutics, Inc. (AXSM) NASDAQ
156.92
-1.95999(-1.23%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
156.92
-1.95999(-1.23%)
Currency In USD
| Previous Close | 158.88 |
| Open | 159.01 |
| Day High | 160.03 |
| Day Low | 155.42 |
| 52-Week High | 191.5 |
| 52-Week Low | 86.99 |
| Volume | 802,076 |
| Average Volume | 679,027 |
| Market Cap | 8.03B |
| PE | -42.53 |
| EPS | -3.69 |
| Moving Average 50 Days | 174.32 |
| Moving Average 200 Days | 137.24 |
| Change | -1.96 |
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms
GlobeNewswire Inc.
Feb 24, 2026 12:00 PM GMT
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in
Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 18, 2026 12:00 PM GMT
NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will present at the Oppenheimer
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.
GlobeNewswire Inc.
Feb 17, 2026 12:00 PM GMT
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a sett